# A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

> **NCT02763566** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 463 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02763566
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-05
- **Primary completion:** 2019-03-29
- **Final completion:** 2028-03
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763566, "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02763566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*